Dr.SABYASACHI BANDYOPADHYAY, S12267
Aim: To study the efficacy and safety of topical Loteprednol Etabonate (LE) 0.5% versus Cyclosporine A(Cs A) 0.05% in Vernal Keratoconjunctivitis (VKC).
Methods: Among 64 VKC patients, 32 cases were treated with topical LE 0.5% and 32 with topical Cs A 0.05%. Disease scores were assigned with symptoms (itching, tearing, photophobia, discharge) and signs (tarsal papilla, corneal involvement, limbal papilla, conjunctival hyperemia).
Results: Mean disease score improved to 8.56±1.92 on day 7 from baseline (14.12±3.39) (p<0.0001) in LE group and to 11.37± 3.07 on day 7 from baseline(14.09±3.68) in Cs A group (p<0.0001). All the signs and symptoms improved in both the groups from day 7 onwards except tarsal papilla and corneal involvement in Cs A group which improved from day 14. There was no significant rise of intraocular pressure in either group. Conclusion: Both topical LE 0.5% and Cs A 0.05% are safe and effective in VKC but the former is more effective.
PRESENTATION NOT RECEIVED FROM THE AUTHOR.
Leave a Comment